biostudies-literatureJosa-Laorden CInstituto de Salud Carlos IIIEuropean UnionInstituto de Salud Carlos III (ISCIII)3741-3749https://www.ebi.ac.uk/biostudies/studies/S-EPMC12450796biostudies-literatureUnknown12(5)<h4>Aims</h4>Effective decongestion is crucial in managing acute decompensated heart failure (ADHF). Persistent congestion post-diuretic therapy correlates with adverse outcomes. This study evaluates whether a strategy guided by intra-abdominal pressure (IAP) and point-of-care ultrasound (POCUS) enhances decongestion compared to standard diuretic titration.<h4>Methods and results</h4>ABDOPOCUS-HF is a randomized, multicentre, open-label, pragmatic clinical trial involving 168 patients hospitalized with ADHF across 14 Spanish hospitals. Inclusion criteria encompass clinical signs of congestion and elevated natriuretic peptides (NT-proBNP >1000 pg/mL or BNP > 250 pg/mL). Participants are randomized 1:1 to either standard care or an intervention arm where diuretic therapy is guided by baselinESC heart failureThe role of intra-abdominal pressure and point of care ultrasound to guide decongestive therapies in acute heart failure.PMC12450796PI23/00797Garcia-Lorente NTorres-Macho JTrullas JCSalamanca-Bautista PFernandez-Villa NJosa-Laorden CCampos-Saenz de Santamaria ARubio-Gracia JTorres-Courchoud ICobo-Marcos MPinilla MJMartinez-Gutierrez RSerrano-Irigoyen PPerez-Silvestre JMendez-Bailon MLlacer-Iborra PMorales-Rull JLSanchez-Marteles MMontero-Hernandez EVazquez-Ronda MACrespo-Aznarez SfalseThe role of intra-abdominal pressure and point of care ultrasound to guide decongestive therapies in acute heart failure.<h4>Aims</h4>Effective decongestion is crucial in managing acute decompensated heart failure (ADHF). Persistent congestion post-diuretic therapy correlates with adverse outcomes. This study evaluates whether a strategy guided by intra-abdominal pressure (IAP) and point-of-care ultrasound (POCUS) enhances decongestion compared to standard diuretic titration.<h4>Methods and results</h4>ABDOPOCUS-HF is a randomized, multicentre, open-label, pragmatic clinical trial involving 168 patients hospitalized with ADHF across 14 Spanish hospitals. Inclusion criteria encompass clinical signs of congestion and elevated natriuretic peptides (NT-proBNP >1000 pg/mL or BNP > 250 pg/mL). Participants are randomized 1:1 to either standard care or an intervention arm where diuretic therapy is guided by baselin2025-01-01T00:00:00Z2025 Oct2026-06-03T17:30:08.922Z2026-04-30T03:07:16.305ZS-EPMC124507964073977810.1002/ehf2.15380